English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters

Valet, G., Repp, R., Link, H., Ehninger, A., & Gramatzki, M. (2003). Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry Part B-Clinical Cytometry, 53B(1), 4-10.

Item is

Basic

show hide
Genre: Journal Article
Alternative Title : Cytom. Part B-Clin. Cytom.

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Valet, G.1, Author           
Repp, R., Author
Link, H., Author
Ehninger, A., Author
Gramatzki, M., Author
Affiliations:
1Former Research Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565145              

Content

show
hide
Free keywords: acute myeloid leukemia (AML); predictive medicine; personalized medicine; clinical cytomics; data sieving; medical bioinformatics
 Abstract: Background: The goal of this study concerned the pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients by data pattern analysis from flow cytometric immunophenotype, cytogenetic, and clinical data. Methods: Sixty-seven parameters of AML patients at diagnosis were classified for predictive information by algorithmic data sieving using iteratively self optimizing triple matrix data pattern analysis (http://www.biochem.mpg.de/valet/classif1.html). Results: Pretherapeutic predictive values for nonsurvival within five years and two years were 100.0% and 83.2%, respectively, compared to 13.9% and 47.4% for the prediction of survival at five years and two years, respectively. At diagnosis, five-year nonsurvivors showed increased patient age and higher concentration of cells in the analyzed specimen, as well as increased levels of % CD2, CD4, CD13, CD36, and CD45 positive AML blasts. Two-year nonsurvivors were characterized by a data pattern of increased patient age and levels of % CD4, CD7, CD11b, CD24, CD45, TH126, and HLA-DR positive AML blasts and decreased levels of % CD1, CD65, CD95, and TC25 positive AML blasts. Cytogenetic abnormalities were not selected for the optimized discriminatory data patterns. Conclusions: The comparatively accurate pretherapeutic identification of high- risk AML patients may prove useful for the development of individualized therapy protocols in stratified clinical patients groups. (C) 2003 Wiley-Liss, Inc.

Details

show
hide
Language(s): eng - English
 Dates: 2003-05
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 41379
ISI: 000182718100002
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Cytometry Part B-Clinical Cytometry
  Alternative Title : Cytom. Part B-Clin. Cytom.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 53B (1) Sequence Number: - Start / End Page: 4 - 10 Identifier: ISSN: 0196-4763